Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

NovaBay Pharmaceuticals Q4 EPS $(0.21) Beats $(0.30) Estimate, Sales $3.73M Beat $3.40M Estimate

Author: Benzinga Newsdesk | March 26, 2024 05:18pm
NovaBay Pharmaceuticals (AMEX:NBY) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.30) by 30 percent. This is a 85.71 percent increase over losses of $(1.47) per share from the same period last year. The company reported quarterly sales of $3.73 million which beat the analyst consensus estimate of $3.40 million by 9.62 percent. This is a 2.31 percent increase over sales of $3.64 million the same period last year.

Posted In: NBY


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist